---
title: "Entyvio (vedolizumab) in ulcerative colitis: Guidelines questions"
description: "Guidelines questions on Entyvio (vedolizumab) in ulcerative colitis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What do ACG guidelines recommend about Entyvio for ulcerative colitis? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/guidelines"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Entyvio (vedolizumab) in ulcerative colitis: Guidelines questions

Manufacturer: Takeda Pharmaceuticals U.S.A., Inc.  
Prescribing information: [Entyvio](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1)

Questions that apply to every indication of Entyvio are on [Entyvio (vedolizumab), all indications](https://www.evicenter.com/medical-information/entyvio).

## Guidelines

<a id="entyvio-acg-guideline"></a>

### What do ACG guidelines recommend about Entyvio for ulcerative colitis?

> “In patients with moderately to severely active UC, the ACG recommends ENTYVIO (vedolizumab) 
> for induction of remission (strong recommendation, moderate quality of evidence) 
> ACG recommends continuing ENTYVIO (vedolizumab) for maintenance of remission (IV infusion 
> or the ENTYVIO Pen) in patients with prior moderately to severely active UC now in remission after 
> ENTYVIO induction (strong recommendation, moderate quality of evidence) 
> In patients with moderately to severely active UC, the ACG recommends ENTYVIO (vedolizumab) 
> as compared to Humira<sup>®</sup> (adalimumab) for maintenance of remission (strong recommendation, 
> moderate quality of evidence) 
> Please refer to the publication for a full list of recommendations from the ACG clinical guidelines for 
> adults with UC.”

Source: [ENTYVIO: select guideline updates for ENTYVIO, page 2, captured 2026-11-13](https://www.entyviohcp.com/content/dam/takeda/imported/entyvio/pdfs/updated-acg-guidelines.pdf#page=2)

> “1. Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. Am J Gastroenterol. 2025;120(6):1187-
> 1224.”

Source: [ENTYVIO: select guideline updates for ENTYVIO, page 4, captured 2026-11-13](https://www.entyviohcp.com/content/dam/takeda/imported/entyvio/pdfs/updated-acg-guidelines.pdf#page=4)

Note: Takeda's summary of selected recommendations from the 2025 American College of Gastroenterology ulcerative colitis guideline (reference 1); the document directs readers to the publication for the full list of recommendations. The recommendation wording is Takeda's (document US-VED-3906v4.0, 03/26).

## Related pages
- [Medical information: Entyvio (vedolizumab): Ulcerative colitis](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis)
- [Indication](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/access-and-coverage)
